ing emergency assistance and providing naloxone 
and other first aid in order to save a life. 
(10) The American Medical Association (AMA), 
the Nation’s largest physician organization, supports 
further implementation of community-based pro-
grams that offer naloxone and other opioid overdose 
prevention services. 
(11) Community-based overdose prevention pro-
grams have successfully prevented deaths from 
opioid overdoses by making rescue trainings and 
naloxone available to first responders, parents, and 
other bystanders who may encounter an overdose. A 
CDC report credits overdose prevention programs 
with saving more than 10,000 lives since 1996. 
(12) At least 188 local overdose prevention pro-
grams are operating in the United States, including 
in major cities such as Baltimore, Chicago, Los An-
geles, New York City, Boston, San Francisco, and 
Philadelphia, and statewide in New Mexico, Massa-
chusetts, and New York. In New Mexico, which has 
one of the highest drug overdose death rates in the 
country, health officials estimate the statewide 
naloxone distribution program that began in 2001 
has reversed 3,000 overdoses. Another program in 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
Wilkes County, North Carolina, reduced overdose 
deaths 69 percent between 2009 and 2011. 
(13) Overdose prevention programs are needed 
in correctional facilities, addiction treatment pro-
grams, and other places where people are at higher 
risk of overdosing after a period of abstinence. 
(14) A real-time overdose surveillance and re-
porting database is needed to monitor fatal and 
nonfatal drug overdoses, identify areas of the coun-
try in need of programmatic support, monitor the 
outcomes of overdose occurrences, and enhance eval-
uation of community programs and interventions. 
SEC. 3. OVERDOSE PREVENTION GRANT PROGRAM. 
(a) PROGRAM AUTHORIZED.—The Director of the 
Centers for Disease Control and Prevention shall award 
grants or cooperative agreements to eligible entities to en-
able the eligible entities to reduce deaths occurring from 
overdoses of drugs. 
(b) APPLICATION.— 
(1) IN GENERAL.—An eligible entity desiring a 
grant or cooperative agreement under this section 
shall submit to the Director an application at such 
time, in such manner, and containing such informa-
tion as the Director may require. 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
(2) CONTENTS.—An application under para-
graph (1) shall include— 
(A) a description of the activities to be 
funded through the grant or cooperative agree-
ment; and 
(B) a demonstration that the eligible entity 
has the capacity to carry out such activities. 
(c) PRIORITY.—In awarding grants and cooperative 
agreements under subsection (a), the Director shall give 
priority to eligible entities that— 
(1) are a public health agency or community- 
based organization; and 
(2) have expertise in preventing deaths occur-
ring from overdoses of drugs in populations at high 
risk of such deaths. 
(d) ELIGIBLE ACTIVITIES.—As a condition on receipt 
of a grant or cooperative agreement under this section, 
an eligible entity shall agree to use the grant or coopera-
tive agreement to carry out one or more of the following 
activities: 
(1) Purchasing and distributing the drug 
naloxone. 
(2) Educating physicians and pharmacists 
about overdose prevention and naloxone prescription. 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
(3) Training first responders, other individuals 
in a position to respond to an overdose, and law en-
forcement and corrections officials on the effective 
response to individuals who have overdosed on 
drugs. 
(4) Implementing and enhancing programs to 
provide overdose prevention, recognition, treatment, 
and response to individuals in need of such services. 
(5) Expanding a program described in para-
graph (1), (2), or (3). 
(e) REPORT.—As a condition on receipt of a grant 
or cooperative agreement under this section, an eligible en-
tity shall agree to prepare and submit, not later than 90 
days after the end of the grant or cooperative agreement 
period, a report to the Director describing the results of 
the activities supported through the grant or cooperative 
agreement. 
(f) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated such sums as may be 
necessary to carry out this section for each of the fiscal 
years 2013 through 2017. 
SEC. 4. SENTINEL SURVEILLANCE SYSTEM. 
(a) DATA COLLECTION.—The Director of the Centers 
for Disease Control and Prevention shall annually compile 
and publish data on both fatal and nonfatal overdoses of 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
drugs for the preceding year. To the extent possible, the 
data shall be collected from all county, State, and tribal 
governments, the Federal Government, and private 
sources (such as the National Poison Data System), shall 
be made available in the form of an Internet database that 
is accessible to the public, and shall include— 
(1) identification of the underlying drugs that 
led to fatal overdose; 
(2) identification of substance level specificity 
where possible; 
(3) analysis of trends in polydrug use in over-
dose victims, as well as identification of emerging 
overdose patterns; 
(4) results of toxicology screenings in fatal 
overdoses routinely conducted by State medical ex-
aminers; 
(5) identification of— 
(A) drugs that were involved in both fatal 
and nonfatal unintentional poisonings; and 
(B) the number and percentage of such 
poisonings by drug; and 
(6) identification of the type of place where un-
intentional drug poisonings occur, as well as the age, 
race, and gender of victims. 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS